Author

Alvin Kamili

UNSW SydneyORCID 0000-0002-4864-1195Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Jamie I. FletcheriD· 3 shared Andrew J. GiffordiD· 2 shared Angela LiniD· 2 shared Chelsea MayohiD· 2 shared Lujing CuiiD· 2 shared M. Emmy M. DolmaniD· 2 shared Marie WongiD· 2 shared Michelle HaberiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Jamie I. FletcherORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN-amplified high-risk neuroblastoma

Alvin Kamili, Brandon A. Hearn, Isabella Temelkoska, Joan Solomon, Madeleine S. Wheatley, Christina H.T. Bui, Caroline J. Atkinson, Leith-Justin Elhassadi, Sadia Qureshi, Jayne E. Murray, Roxanne Cadiz, Andrew J. Gifford, Lujing Cui, Lewis Crowley, Angela Lin, , Jamie I. Fletcher

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

bioRxiv · Sep 10, 2026 · PreprintCancer Biology

Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma

Jeremy Z. R. Han, Monica Phimmachanh, Jordan F. Hastings, King Ho Leong, Boaz H. Ng, Jing Ni, Angela Fontaine-Titley, Antonia L. Cadell, Yolande E. I. O’Donnell, Misaki S. Clearwater, Alvin Kamili, Michelle Haber, Murray D. Norris, Paul Timpson, Toby N. Trahair, , David R. Croucher

The paper identifies JNK-independent drugs that, when combined with standard chemotherapy, improve response in relapsed high-risk neuroblastoma by exploiting differential apoptotic network utilization.

Science Advances · Nov 28, 2025Peer-reviewedCancer Biology

Engineered paediatric tumours retain patient tumour genotype and phenotype for precision medicine.

MoonSun Jung, Valentina Poltavets, Joanna N. Skhinas, Gábor Tax, Alvin Kamili, Jinhan Xie, Sarah Ghamrawi, Philipp Graber, Jie Mao, Marie Wong, Lujing Cui, Kathleen Kimpton, Pooja Venkat, Chelsea Mayoh, Angela Lin, , Maria Kavallaris

This paper develops patient-derived tumour models using engineered ECM hydrogels to enable precision medicine for paediatric cancers by retaining tumour genotype and phenotype.

Molecular Systems Biology · Oct 1, 2025Peer-reviewedCancer Biology